A patient is described who presented with a 10 year history of intermittent peptic ulcer symptoms and a 3 year history of an undiagnosed skin rash. Investigations indicated raised plasma levels of gastrin, glucagon and pancreatic polypeptide. A single tumour was localised to the pancreas and resected. The tumour had the typical histology of an apudoma, and contained cells which stained for gastrin, glucagon, pancreatic polypeptide and neurotensin.
Introduction
It is becoming increasingly recognised that pancreatic endocrine tumours (apudomas) may contain more than one peptide hormone (Abe et al., 1979; Heitz et al., 1979) . Nevertheless, individual patients whose tumours have not metastasised present with a single clinical syndrome due to over-production of one of the peptides. We report a patient who presented with the combined features of ZollingerEllison (gastrinoma) and glucagonoma syndromes in whom hypersecretion of 3 peptides was demonstrated. (Bloom, Adrian and Polak, 1980) . Somatostatin and vasoactive intestinal peptide levels were normal.
Upper abdominal ultrasound, computed tomography and arteriography localised a single avascular tumour in the head of the pancreas. The ulcers failed to respond to high-dose cimetidine therapy and, despite continued therapy, his skin problems remained. He Clinical reports therefore underwent laparotomy and a single 9 cm diameter hypovascular tumour was .removed from the head of the pancreas in a Whipple's procedure. Histological examination showed a typical endocrine tumour which, on immunocytochemistry, was shown to contain approximately equal proportions of 3 types of cells, staining for gastrin, glucagon, and pancreatic polypeptide respectively with, in addition, a few sparsely scattered neurotensin cells. Electron microscopy showed the presence of 4 cell types in the tumour. Radioimmunoassay of tumour extracts confirmed presence of gastrin (280 pmol/g wet weight) glucagon (119 pmol/g) and pancreatic polypeptide (80 pmol/g). Postoperative measurements of fasting plasma hormones showed that these had fallen to normal levels indicating origin from the single tumour. The patient, following an initial good recovery, died after recurrent surgery for persistent pancreatic anastomosis fistula problems 6 weeks after surgery.
Discussion
Pancreatic polypeptide production has been described previously in patients with pancreatic endocrine tumours associated with typical syndromes and does not, in itself, produce symptoms (Welbourn et al., 1981) . However, although secretion ofgastrin and glucagon has been reported in a patient who presented with an insulinoma (Broder and Carter, 1973) , there have been no previous reports of the hypersecretion of gastrin, glucagon and pancreatic polypeptide and no reports of the co-existence of the clinical syndromes ascribed to hypergastrinaemia and hyperglucagonaemia in a single patient. This patient undoubtedly had features ascribed to over-production of both hormones for 9 years, having been noted to have glycosuria and a duodenal ulcer in 1971 and severe clinical problems for 3 years before diagnosis. The case emphasises the slow growth and potential of endocrine pancreatic tumours to secrete more than one hormone. It demonstrates the need for awareness of the presence of such tumours when patients manifest unusual combinations of symptoms, even when these symptoms are of long standing. 
